Tarlatamab for advanced extrapulmonary neuroendocrine carcinoma
Treatments studied
Part of Cancer clinical trials.
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 19 years old.
- Your cancer must be a type called 'extrapulmonary neuroendocrine carcinoma' (cancer that started outside the lungs) and has come back or not responded to a platinum-based chemotherapy.
- Your cancer must have started in the digestive tract (stomach, esophagus, small intestine, colon, rectum, pancreas, or bile ducts) OR in the urinary/genital area (prostate, bladder, ureter, urethra, or kidney).
- You must have at least one tumor that can be measured on a scan (CT or MRI).
- You must be in reasonably good health, able to walk and take care of yourself, and have adequate organ function (kidneys, liver, blood counts, and heart).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This trial tests a new drug called Tarlatamab for people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) of the digestive system that has stopped responding to prior chemotherapy. The drug targets a protein called DLL3 found on some tumors, and researchers hope it can shrink or slow tumor growth.
This study tests an investigational drug called tarlatamab in people with a rare type of cancer called neuroendocrine carcinoma that started in the female reproductive tract (cervix, vulva, or vagina). The goal is to see if tarlatamab can shrink or control the cancer. To participate, your cancer must have progressed after at least one line of platinum-based chemotherapy. You must also have measurable disease and be willing to provide a tumor sample.
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
This trial tests a drug called tarlatamab for people with advanced prostate cancer that has a specific protein (DLL3) on their tumor cells. The goal is to see if tarlatamab can help shrink or slow the cancer.
Hear when a new Neuroendocrine Carcinomas (NEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.